Product Images Lisdexamfetamine Dimesylate

This is a medication label for Lisdexamfetamine Dimesylate Capsules with each capsule containing 10 mg of Lisdexamfetamine Dimesylate (equivalent to 5.8 mg lisdexamfetamine). The medication guide should be provided to each patient, and dosage information can be found in the package insert. The capsules should be stored at room temperature and dispensed in a tight, light-resistant container with a child-resistant closure. The medication is manufactured by Granules Pharmaceuticals Inc., located in Chantilly, VA. More information can be found at htfps://granulespharma.com/products/lisdexamfetamine-caps.*

This text provides information about a prescription medication called Lisdexamfetamine Dimesylate Capsules. The capsules contain 20 mg of Lisdexamfetamine dimesylate, which is equivalent to 11.6 mg of lisdexamfetamine. The pharmacist is instructed to dispense the Medication Guide provided separately to each patient. It is recommended to store the medication at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). Further dosage information can be found in the package insert. The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The manufacturer is Granules Pharmaceuticals Inc., located in Chantilly, VA, with a revision date of 10/2024. Reference is made to the USP Controlled Room Temperature guidelines.*

This is a prescription medication in the form of capsules containing Lisdexamfetamine Dimesylate. Each capsule contains 30 mg of Lisdexamfetamine Dimesylate (equivalent to 17.3 mg of lisdexamfetamine). The medication guide should be dispensed to each patient. Dosage information can be found in the package insert. It should be stored at room temperature between 20°C to 25°C (68°F to 77°F). Dispense in a tight, light-resistant container with a child-resistant closure. The medication is manufactured by Granules Pharmaceuticals Inc. in Chantilly, VA.*

This text provides details about a medication in capsule form with each capsule containing 40mg of Lisdexamfetamine dimesylate. It is manufactured by Granules Pharmaceuticals Inc. with an address in Chantilly, VA. The text also mentions storage instructions, package insert for dosage information, and advises dispensing in a light-resistant container with a child-resistant closure as per USP guidelines. Lastly, it encourages printing Medication Guides available at the website mentioned.*

This is a prescription medication called Lisdexamfetamine Dimesylate in capsule form. Each capsule contains 50 mg of Lisdexamfetamine Dimesylate, which is equivalent to 28.9 mg of lisdexamfetamine. The pharmacist should dispense the medication along with the Medication Guide provided to each patient. The dosage information can be found in the package insert. The medication should be stored at room temperature (20°C to 25°C), and dispensed in a light-resistant container with a child-resistant closure. For more details, refer to the manufacturer's website.*

This text is a label for Lisdexamfetamine capsules, which are used for prescription medication. Each capsule contains Lisdexamfetamine dimesylate 60mg. It provides storage instructions, dosage information, and a website to print Medication Guides. The medication is manufactured by Granules Pharmaceuticals Inc. The label also includes a prescription-only NDC number and a revision date of 10/2024.*

The text is about a medication containing Lisdexamfetamine dimesylate 70 mg manufactured by Granules Pharmaceuticals Inc. It indicates that each capsule is equivalent to 40.5 mg of lisdexamfetamine and provides dosage information. The medication should be stored at room temperature. Dispensing guidelines are also included for pharmacists. The medication is available in 100 capsules. More detailed information can be accessed on the website provided.*

This is a list of drugs and their interaction potential with different cytochrome P450 enzyme substrates. Guanfacine and Venlafaxine, among others, are listed along with the type of substrates they interact with. The document also includes information regarding fold change relative to reference.*

Proportion of Subjects with Relapse/Treatment Failure (%) over time (days after randomization) for Placebo and Lisdexamfetamine Dimesylate Capsules can be evaluated using the provided data.*

Not available.*